Disruption of TGF-β Signaling Improves Ocular Surface Epithelial Disease in Experimental Autoimmune Keratoconjunctivitis Sicca

Overview of attention for article published in PLOS ONE, December 2011

Altmetric Badge

Mentioned by

patent: 6 patents

Citations

dimensions_citation: 44 Dimensions

Readers on

mendeley: 67 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 6 patents that reference this research output.

Inhibitor for retinochoroidal disorders

Grant US-11730718-B2

United States of America

22 Aug 2023

Therapeutic agent for keratoconjunctive disorders

Grant US-11471440-B2

United States of America

18 Oct 2022

Inhibitor for retinochoroidal disorders

Grant US-10702502-B2

United States of America

07 Jul 2020

Therapeutic agent for keratoconjunctive disorders

Grant US-10537556-B2

United States of America

21 Jan 2020

Therapeutic agent for keratoconjunctive disorders

Grant US-10016395-B2

United States of America

10 Jul 2018

COMPOSITIONS AND METHODS FOR THE TREATMENT OF DRY EYE DISEASE

Application WO-2013148155-A1

World Intellectual Property Organisation (WIPO)

03 Oct 2013

PLOS

Article Metrics

Disruption of TGF-β Signaling Improves Ocular Surface Epithelial Disease in Experimental Autoimmune Keratoconjunctivitis Sicca

Mentioned by

Citations

Readers on

Inhibitor for retinochoroidal disorders

Grant US-11730718-B2

United States of America

Therapeutic agent for keratoconjunctive disorders

Grant US-11471440-B2

United States of America

Inhibitor for retinochoroidal disorders

Grant US-10702502-B2

United States of America

Therapeutic agent for keratoconjunctive disorders

Grant US-10537556-B2

United States of America

Therapeutic agent for keratoconjunctive disorders

Grant US-10016395-B2

United States of America

COMPOSITIONS AND METHODS FOR THE TREATMENT OF DRY EYE DISEASE

Application WO-2013148155-A1

World Intellectual Property Organisation (WIPO)